Morphosys sees revenue boost as FDA approves psoriasis drug

DUESSELDORF/FRANKFURT (Reuters) - German biotech group Morphosys expects to receive royalties for its psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news